SeekingAlphaAugust 9, 2026 at 11:51 PM NY25 days ago

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement

Corvus Pharma (CRVS) Strong Buy: soquelitinib PTCL & atopic dermatitis catalysts, key 2027 readouts, $215M cash to Q2 2028âread now.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — SeekingAlpha

Companies in This Story